The hallmark of endochondral bone development is the presence of cartilaginous templates, in which osteoblasts and stromal cells are generated to form mineralized matrix and support bone marrow haematopoiesis. However, the ultimate source of these mesenchymal cells and the relationship between bone progenitors in fetal life and those in later life are unknown. Fate-mapping studies revealed that cells expressing cre-recombinases driven by the collagen II (Col2) promoter/enhancer and their descendants contributed to, in addition to chondrocytes, early perichondrial precursors before Runx2 expression and, subsequently, to a majority of osteoblasts, Cxcl12 (chemokine (C-X-C motif) ligand 12)-abundant stromal cells and bone marrow stromal/mesenchymal progenitor cells in postnatal life. Lineage-tracing experiments using a tamoxifen-inducible creER system further revealed that early postnatal cells marked by Col2-creER, as well as Sox9-creER and aggrecan (Acan)-creER, progressively contributed to multiple mesenchymal lineages and continued to provide descendants for over a year. These cells are distinct from adult mesenchymal progenitors and thus provide opportunities for regulating the explosive growth that occurs uniquely in growing mammals.
A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones Noriaki Ono 1,2 , Wanida Ono 1,2 , Takashi Nagasawa 3,4 and Henry M. Kronenberg 1, 5 The hallmark of endochondral bone development is the presence of cartilaginous templates, in which osteoblasts and stromal cells are generated to form mineralized matrix and support bone marrow haematopoiesis. However, the ultimate source of these mesenchymal cells and the relationship between bone progenitors in fetal life and those in later life are unknown. Fate-mapping studies revealed that cells expressing cre-recombinases driven by the collagen II (Col2) promoter/enhancer and their descendants contributed to, in addition to chondrocytes, early perichondrial precursors before Runx2 expression and, subsequently, to a majority of osteoblasts, Cxcl12 (chemokine (C-X-C motif) ligand 12)-abundant stromal cells and bone marrow stromal/mesenchymal progenitor cells in postnatal life. Lineage-tracing experiments using a tamoxifen-inducible creER system further revealed that early postnatal cells marked by Col2-creER, as well as Sox9-creER and aggrecan (Acan)-creER, progressively contributed to multiple mesenchymal lineages and continued to provide descendants for over a year. These cells are distinct from adult mesenchymal progenitors and thus provide opportunities for regulating the explosive growth that occurs uniquely in growing mammals.
Most bones are formed through endochondral bone development, in which mesenchymal condensations first define the domain for the future bones, and then develop into the growth cartilage wherein chondrocytes appear and proliferate. Chondrocytes in the growth plate continue to proliferate well into adulthood in mice 1 . In the centre of the developing cartilage mould, chondrocytes stop proliferating and become hypertrophic chondrocytes. These cells signal to induce the migration of mesenchymal cells into the marrow space; these cells then differentiate into osteoblasts that then form bone on top of the cartilaginous matrix. Perichondrial precursors expressing osterix (Osx) invade into the cartilage template along with blood vessels and eventually become both osteoblasts and stromal cells in the marrow space 2 . However, mesenchymal cells constituting earlier cells of the osteoblast lineage than Osx + precursors in vivo have not been fully characterized. The transcription factor Sox9 is expressed in mesenchymal condensations, and osteochondroprogenitors are derived from Sox9 + cells, as Sox9-cre marks all chondrocytes and osteoblasts 3 . Sox9 binds to genes encoding major cartilaginous matrix proteins such as aggrecan (Acan) and type II collagen-α1 (Col2a1) and regulates their expression. How these early osteochondroprogenitors and their descendants relate to mesenchymal precursors in adult bone is unknown. In adult endochondral bones, the source of osteoblasts and stromal cells has been proposed to be mesenchymal stem cells (MSCs) or bone marrow stromal/mesenchymal progenitor cells (BMSCs), which are traditionally defined as cells capable of forming colonies in vitro (CFU-Fs: colony-forming unit fibroblasts) that can undergo multilineage differentiation in vitro and on transplantation 4 . CFU-Fs are enriched among various adult marrow populations such as nestin (Nes)-GFP + cells 5 , platelet-derived growth factor receptorα (PDGFRα) + Sca1 + CD45 − Ter119 − (PαS) cells 6 and leptin receptor (LepR)/LepR-cre + cells 7 in mice and CD146 + pericytes in humans 8 . In this study, we sought to identify cells that robustly supply osteoblasts and stromal cells in the metaphyses of growing bones and suggest the possibility that these cells might be the source of MSCs/BMSCs in adult bone marrow.
RESULTS
Col2-cre/Col2-creER are expressed in early cells of the osteoblast lineage in fetal mice We chose to explore the hypothesis that cells defined by activities of the Sox9, aggrecan (Acan) and type II collagen (Col2) gene promoter/enhancers might encompass mesenchymal precursors of osteoblasts and stromal cells. Previous studies indicate that osteochondroprogenitors are marked by cre recombinases driven by the Col2a1 promoter [9] [10] [11] [12] . First, we mapped cell fates using a Col2-cre; R26R-tdTomato reporter 13, 14 in combination with Col1(2.3kb)-GFP (ref. 15 ) as a readout of osteoblastic cells. In this system, cells expressing Col2-cre and their descendants become red, and if they concurrently express Col1-GFP, they become yellow. In addition, a thymidine analogue, EdU, was administered shortly before analysis to evaluate cell proliferation. At embryonic day 12.5 (E12.5), red cells were observed in the growth cartilage ( Fig. 1a , asterisks) and perichondrium (Fig. 1a, sharps) , where many of these cells were proliferating (see also Supplementary Fig. 1a for an earlier day). At E14.5, almost all Col1-GFP + cells appearing in the osteogenic perichondrium were yellow ( Fig. 1b, arrowheads) ; thus, these perichondrial preosteoblasts were derived from Col2-cre + cells. Active cell proliferation was observed in the perichondrium, but not in its adjacent hypertrophic chondrocytes ( Fig. 1b ). At E15.5, Col2-cre-derived cells proliferated within the marrow space, as the nascent primary ossification centre was occupied by red cells (Fig. 1c , asterisks).
Second, we mapped cell fates using an Osx-cre::GFP; R26R-tdTomato reporter 16 . In this system, cells expressing Osx-cre::GFP become green in the nucleus, and these cells and their descendants become red. At E12.5, Osx + yellow cells (expressing Osx-cre::GFP and tdTomato) were observed in the growth cartilage and perichondrium, in a domain more restricted than that of Col2-cre-targeted cells ( Fig. 1d, arrows) . At E14.5, Osx + yellow cells dominated the inner part of the perichondrium in a domain broader than Col1 + cells seen in Fig. 1b (Fig. 1e , arrows), with some of them in proliferation ( Supplementary Fig. 1f ,g). Osx + prehypertrophic chondrocytes appearing green were not proliferating ( Fig. 1e , arrowheads). At E15.5, mesenchymal cells appearing in the primary ossification centre were largely yellow ( Fig. 1f , asterisks), and therefore expressing Osx. These comparative fate-mapping analyses suggest that one fate of Col2 + cells may be to become Osx + cells in the perichondrium and the marrow space.
Runx2 is a crucial transcription factor in osteoblastic differentiation genetically upstream of Osx (ref. 17). To understand whether Col2 + cells require Runx2 expression, as, for example, nestin-GFP + perichondrial cells do 18 , we analysed mice carrying Runx2null alleles 19 in addition to the Col2-cre; R26R-tdTomato; Col1-GFP transgenes. In these mice, no Col1-GFP + cell appeared in the perichondrium at E14.5. However, despite the absence of Runx2, Col2-cre-derived red cells were still present in the perichondrium (Fig. 1g , arrows) and its underlying growth cartilage ( Fig. 1g right panel, arrowheads). Therefore, Runx2 is dispensable for generating these Col2-cre-derived progenitor cells, although it is required for their further differentiation into osteoblasts. This places Col2 + cells in the perichondrium upstream of Runx2 expression in the lineage.
We next examined the distribution of Col2-cre-targeted red cells at postnatal day 3 (P3), when bone marrow haematopoiesis had been established. Col2-cre-targeted red cells contributed not only to chondrocytes and perichondrial cells in the growth cartilage, but also to Col1-GFP + osteoblasts, osteocytes and Cxcl12 high stromal cells 20, 21 in the marrow space ( Fig. 1h ,i, see also Supplementary  Fig. 1b,c) . Osx-cre-targeted red cells contributed to all of these cell types 22, 23 (Fig. 1j ,k, see also Supplementary Fig. 1d,e ). Flow cytometry analysis of dissociated bone cells revealed that Osx-cre-targeted cells contributed to essentially all osteoblasts (95.5 ± 0.7% of Col1-GFP high and 97.8 ± 1.3% of Oc-GFP high ; ref. 15 ) and Cxcl12-expressing stromal cells (92.1 ± 6.9% of Cxcl12-GFP high , n = 3 per group, data are presented as mean ± s.d.; ref. 24) ( Fig. 1m ). Col2-cre-targeted cells also contributed to a great majority of osteoblasts (80.0 ± 2.8% of Col1-GFP + and 78.1 ± 5.9% of Oc-GFP + ) and Cxcl12-expressing stromal cells (89.6 ± 5.2% of Cxcl12-GFP high , n = 3 per group, data are presented as mean ± s.d.) ( Fig. 1l ). Therefore, most osteoblasts and Cxcl12-expressing stromal cells in endochondral bones are derived from mesenchymal progenitors/precursors that express Col2-cre and Osx-cre at some point in their development.
To further clarify the relationships between Col2 + cells and Osx + cells within the mesenchymal lineage, we took advantage of tamoxifen-inducible creER recombinases (Col2-creER (ref. 25) or Osx-creER (ref. 2)) and performed pulse-chase experiments with a single tamoxifen injection. An E11.5 pulse to Col2-creER mice marked perichondrial cells and chondrocytes at E12.5 (Fig. 2a ), and their descendants (Col2 creER -E11.5) contributed to the perichondrium and the primary ossification centre at E15.5 ( Fig. 2b) and yielded a number of tdTomato + cells throughout the bone at P0 ( Fig. 2c ) and P21 ( Supplementary Fig. 2a ). In contrast, an E11.5 pulse to Osx-creER mice did not give rise to descendants at P0 ( Fig. 2d ), suggesting that Col2-creER + cells appeared earlier than Osx-creER + cells during early skeletal development. An E13.5 pulse to Col2-creER mice marked chondrocytes beneath the perichondrium, as well as perichondrial cells, at E14.5 ( Fig. 2e ), and their descendants (Col2 creER -E13.5) contributed to the primary ossification centre at E16.5 (Fig. 2f ). Col2 creER -E13.5 cells continued to yield tdTomato + cells robustly in the growth cartilage, the perichondrium and the bone at P0 ( Fig. 2g ) and including the secondary ossification centre in the epiphyseal region at P21 ( Fig. 2h ). Osx-creER + cells at E13.5 proliferate in the primary ossification centre at E16.5 (ref.
2) but do not persist in the perichondrium 18 . Their descendants (Osx creER -E13.5) appeared as osteoblasts and stromal cells among cells derived from the primary ossification centre, but not those of the secondary ossification centre at P0 (Fig. 2i ), and then gradually disappeared from the metaphysis by P21 ( Fig. 2j and Supplementary Fig. 2b ). These data underscore the transient nature of embryonic Osx-creER + cells, supporting the notion that these cells are replenished by their precursors, probably derived from Col2-creER cells during early bone development.
Col2-creER-expressing cells at an early postnatal stage generate multiple mesenchymal lineages
As cells expressing Col2-creER in fetal life seem to be early cells in the osteoblast lineage, we next investigated whether this transgene is also active in postnatal life. For this purpose, Col2-creER; R26R-tdTomato 25 mice were pulsed with a low-dose tamoxifen injection at P3. A small number of tdTomato + cells were detected at P5 and P10 in the absence of tamoxifen administration ( Supplementary Fig. 2d ,e). Two days after a tamoxifen pulse at P3 (Col2 creER -P3), chondrocytes in the growth plate and beneath the perichondrium, as well as cells in the perichondrium and metaphyseal spongiosa, were labelled by Col2-creER ( Fig. 4a ). After a week, a group of Col2 creER -P3 cells appeared directly under the growth plate in the primary spongiosa and beneath the unlabelled cells of the perichondrium with further contiguity to the endocortical surface ( Fig. 3a also Fig. 4b ). After a month, Col2 creER -P3 cells became osteoblasts and stromal cells in the metaphysis and epiphysis, in addition to chondrocytes in the growth plate and articular cartilage ( Fig. 3b , see also Fig. 4e ). During an extended chase period over a year after the pulse, Col2 creER -P3 cells continued to yield chondrocytes, osteoblasts and stromal cells in the metaphysis, and also became adipocytes in the metaphyseal bone marrow (Fig. 3c,d and Supplementary Fig. 2f ). Of note, Col2-creER does not mark marrow cells in the middle of the diaphysis at P3, even though Col2-cre marks all stromal and osteoblastic regions of bone. Presumably, this contrast results from the Col2 promoter driving the expression of creER no longer being active in marrow stromal cells in the diaphysis at P3. The contrast between the cells marked by Col2-creER and Osx-creER transgenes is instructive. Shortly after the pulse, most osteoblasts on the bone surface and cells in the perichondrium were marked by Osx-creER ( Fig. 4c) . After a week of chase, Osx creER -P3 cells continued to be present on the bone surface and in the marrow space ( Fig. 3e , see also Fig. 4d ). After a month, Osx creER -P3 cells became osteoblasts and stromal cell in the metaphysis and diaphysis, but not in the epiphysis (Fig. 3f, see also Fig. 4f) . In contrast to the persistence of Col2 creER -P3 cells in the one-year chase, Osx creER -P3 cells gradually disappeared from the metaphysis and became increasingly present as stromal cells in the diaphyseal bone marrow and osteoblasts on the endocortical surface ( Fig. 3g,h,m and Supplementary Fig. 2c ). The Osx-creER; R26R-tdTomato system had little to no tamoxifenindependent activities (Fig. 3k,l) . Thus, Osx-creER + cells at P3 generate cells in the metaphysis only transiently, but persist in the marrow stroma for a prolonged period.
To assess quantitatively how cells marked by Col2-creER or Osx-creER contribute differentially to defined cell types over time, we performed flow cytometry analysis of cells isolated from enzymatically digested bones from triple transgenic mice (Col1-GFP or Cxcl12-GFP, Col2-creER or Osx-creER and R26R-tdTomato) with a single tamoxifen injection at P3. Shortly after the pulse, only a small fraction of cells marked by Col2-creER expressed these GFP reporters (48 h after tamoxifen injection, Col1-GFP + ; 3.2 ± 1.2% (n = 4), Cxcl12-GFP high , 0.3 ± 0.1% (n = 3), data are presented as mean ± s.d.), suggesting that Col2-creER + cells were largely distinct from osteoblasts or Cxcl12-expressing stromal cells (Fig. 4g , left panels). The fraction of Col2 creER -P3 cells among osteoblasts and Cxcl12-expressing stromal cells increased progressively as the chase period extended (Col1-GFP + ; from 8.7 ± 2.1% (n = 3), 23.7 ± 1.7% (n = 5), 27.6 ± 1.7% (n = 3) to 29.3 ± 4.6% (n = 6), Cxcl12-GFP high ; from 1.9 ± 0.3% (n = 4), 7.3 ± 3.1% (n = 4), 9.9 ± 1.2% (n = 4) to 13.8 ± 0.5% (n = 4), for the first, second, third and fourth week, respectively, Fig. 4g , middle panels, and Fig. 4i , blue and red lines, data are presented as mean ± s.d.). No increase of tdTomato + cells was observed without tamoxifen injection (Fig. 4g, right panels) . In contrast, 87.9 ± 1.4% (n = 4) and 11.6 ± 3.5% (n = 3) of cells marked by Osx-creER shortly after the pulse were Col1-GFP + osteoblasts and Cxcl12-expressing stromal cells, respectively ( Fig. 4h , left panels, data are presented as mean ± s.d.). The fraction of Osx creER -P3 cells decreased among osteoblasts (58.1 ± 10.9% (n = 7) and 14.9 ± 0.1% (n = 3) for the first and fourth week, respectively, Fig. 4h , upper middle panel, and Fig. 4j , blue line), and increased among Cxcl12expressing stromal cells (49.2 ± 6.3% (n = 3) and 32.9 ± 1.1% (n = 4) for the second and fourth week, respectively, Fig. 4h , lower middle panel, and Fig. 4j , red line, data are presented as mean ± s.d.). These studies reinforce the results from the histological findings that Col2-creER-marked cells robustly contribute to osteoblasts and stromal cells, whereas Osx-creER-marked cells transiently become osteoblasts and persist longer in bone marrow as stromal cells.
Relationship of growth skeletal progenitor cells and adult bone marrow stromal/mesenchymal progenitor cells
To determine the relationship of the growth skeletal stem/progenitor cells that we have defined here with the more traditionally defined BMSCs, we conducted CFU-F assays using unfractionated bone mar-row cells isolated from P5 mice. Quantification of tdTomato + colonies revealed that Col2-cre targeted a higher proportion of CFU-Fs than Osx-cre did (Tomato + CFU-F: Col2-cre; 42.9 ± 6.3%, Osx-cre; 12.0 ± 4.0%, Fig. 5a ,b, see also Supplementary Fig. 3a , n = 4 per group, data are presented as mean ± s.d.), indicating that a larger fraction of BMSCs were derived from Col2-cre + cells than from Osx-cre + cells during development. To understand whether BMSCs themselves express Col2 or Osx, CFU-F assays were performed using bone marrow cells collected from Col2-creER or Osx-creER; R26R-tdTomato mice 2 days after the pulse. Only a small proportion of CFU-Fs were tdTomato + using this protocol (Tomato + CFU-F: Col2-creER; 1.9 ± 1.7%, Osx-creER; 3.0 ± 3.5%, Fig. 5c , see also Supplementary  Fig. 3b , n = 4 per group, data are presented as mean ± s.d.), suggesting that the majority of BMSCs were rather descendants of cells expressing Col2-cre. Second, we conducted flow cytometry analysis of a PαS fraction using dissociated bone cells collected from these mice at P5 ( Supplementary Fig. 3c ). A PαS fraction represents <1% of the CD45 − Ter119 − fraction and is enriched for CFU-Fs (ref. 6 ). Col2-cre targeted a higher proportion of PαS cells than Osx-cre did (Tomato + PαS cells: Col2-cre; 44.0 ± 6.9%, Osx-cre; 15.6 ± 6.9%, Fig. 5d ,e, n = 4 per group, data are presented as mean ± s.d.), as anticipated from the fraction of CFU-Fs marked by these cre lines. A fraction of PαS cells were Cxcl12-GFP high , and a small percentage of Cxcl12-GFP high cells were positive for Sca1; these fractions seemed to decrease with age ( Supplementary Fig. 3d,e ). A great portion of Cxcl12-GFP high cells were PDGFRα + Sca1 − cells (Supplementary Fig. 3f ). Nes-GFP + cells include all CFU-Fs (ref. 5) and are descended from Col2-creER + cells during bone development 18 . Analysis of Nes-GFP; Col2-cre; R26R-tdTomato bone cells revealed that 46.7 ± 5.1% of Nes-GFP + cells were targeted by Col2-cre (Supplementary Fig. 4a , n = 5, data are presented as mean ± s.d.). We further interrogated the PαS fraction using Nes-GFP; Nes-creER; R26R-tdTomato mice and a single tamoxifen injection at P3. A high fraction of PαS cells were marked by Nes-creER and their descendants throughout the entire first month of chase (48 h after the pulse, 41.6 ± 17.8% (n = 5, then 50.4 ± 12.4% (n = 3) and 44.9 ± 2.8% (n = 4) for the second and fourth week of chase, respectively, Fig. 3f ,g, data are presented as mean ± s.d.). Nes-creER-marked cells contributed to Cxcl12-GFP high cells transiently (50.1 ± 4.2% (n = 3), 11.6 ± 2.3% (n = 4) then 6.0 ± 0.8% (n = 3), for the second day, the first and fourth week of chase, respectively, data are presented as mean ± s.d., Supplementary Fig. 4c ), whereas their contribution to endothelial cells is predominant and persistent 18 . Virtually no PαS cells were marked by Col2-creER or Osx-creER shortly after the pulse (0.3 ± 0.4% (n = 4) and 0.7 ± 0.3% (n = 6), respectively, Fig. 5f ,g, data are presented as mean ± s.d.). During the chase, the fraction of PαS cells derived from Osx creER -P3 cells gradually increased (5.2 ± 2.6% (n = 5) and 10.5 ± 6.0% (n = 8) for the second and fourth week, respectively), whereas those derived from Col2 creER -P3 cells only temporarily increased (0.4 ± 0.3% (n = 5), 5.3 ± 2.8% (n = 7), 1.3 ± 1.6% (n = 5) and 1.4 ± 1.3% (n = 9) for the first to fourth week, respectively, data are presented as mean ± s.d.; Fig. 5f,g) . Similarly, an E13.5 pulse to Col2-creER mice marked virtually no PαS cells after two weeks of chase at P7 ( Supplementary Fig. 4b ). Therefore, although postnatal Col2-creER + cells robustly contributed to Col1-GFP + osteoblasts and Cxcl12 high stromal cells during bone growth, their contribution to a PαS fraction seems to be minimal. As Col2-cre + cells do contribute substantially to the PαS population, it is possible that they do so at a time that we have not tested with Col2-creER mice. A PDGFRα + Sca1 − fraction encompasses most BM-SCs (ref. 7) . Col2-cre and Osx-cre also targeted a similar proportion of PDGFRα + Sca1 − cells (Tomato + PDGFRα + Sca1 − cells: Col2-cre; 57.7 ± 14.6%, Osx-cre; 57.2 ± 5.7%, Fig. 5h ,i, n = 4 per group, data are presented as mean ± s.d.). A sizable fraction of PDGFRα + Sca1 − cells was marked by Col2-creER or Osx-creER shortly after the pulse (16.1 ± 5.8% (n = 4) and 34.1 ± 10.0% (n = 6), respectively), whereas only a marginal fraction of the cells was marked by Nes-creER (1.8 ± 1.3% (n = 5), Fig. 5j ,k, data are presented as mean ± s.d.).
We investigated further whether cells defined by promoter/ enhancer activities of other genes involved in early chondrocyte development could, like Col2-creER, be used to mark early cells of the osteoblast lineage in postnatal bone development. For this purpose, we took advantage of Sox9-creER (ref. 26 ) and aggrecan (Acan)-creER (ref. 27) knock-in alleles and performed similar pulse-chase experiments. Shortly after the chase, Sox9-creER marked populations comparable to those marked by Col2-creER ( Supplementary Fig. 5a ), whereas Acan-creER marked a larger number of perichondrial cells ( Supplementary Fig. 5c ). After a week of chase, both Sox9 creER -P3 and Acan creER -P3 cells increased in the metaphyseal spongiosa and endocortical surface (Fig. 6a,b , see also Supplementary Fig. 5b,d) . We further conducted flow cytometry analysis using mice carrying Col1-GFP, Sox9-creER or Acan-creER and R26R-tomato reporter. A small fraction of cells expressed Col1-GFP shortly after the pulse (Sox9-creER; 3.6 ± 0.8%, Acan-creER; 5.0 ± 2.1%, n = 3 per group, data are presented as mean ± s.d.), and the fraction among osteoblasts increased to 55.1 ± 8.2% (Sox9-creER, n = 8) and 65.9 ± 8.2% (Acan-creER, n = 5, data are presented as mean ± s.d.) after 4 weeks of chase (Fig. 6i,j) . Both Sox9 creER -P3 and Acan creER -P3 cells continued to generate osteoblasts and stromal cells at least for 6 months in a pattern that resembled those of Col2 creER -P3 cells (Fig. 6c,f ). Little to no tamoxifen-independent activities was noted with the use of these knock-in lines (Fig. 6g,h) .
DISCUSSION
Our data collectively indicated that cells defined by promoter/ enhancer activities of genes associated with chondrocytes and their precursors, such as Sox9, Col2 and Acan, encompass early mesenchymal progenitors that continue to become chondrocytes, osteoblasts, stromal cells and adipocytes during endochondral bone development. Cre/creER-recombinases driven by the Osx promoter mark a downstream population with limited lineage potential to generate osteoblasts and stromal cells ( Supplementary Fig. 6 , see the diagram). Cells marked by Osx-creER at P3 are not continually generated in the metaphysis, in contrast to cells marked by Sox9-creER, Col2-creER and Acan-creER, but do persist as stromal cells in metaphyseal bone marrow. Any inconsistency between our data and that of ref. 28 is probably due to the length of the chase, because we chased these cells for a longer period of time, for up to 18 months. In addition, when postnatal Col2-creER + cells generated osteoblasts and stromal cells progressively in the metaphysis, there was no comparable increase of Col2-creER + descendants among a PαS fraction. We speculate that this last observation may be relevant to findings recently published in ref. 7 . In that study, it was found that, in adult mice, PαS cells overlapped considerably with those marked by leptin receptor (LepR)-cre and that cells marked with the LepR-cre; R26R-tdTomato progressively marked osteoblasts, but only starting at two months of age. We suggest that the growthassociated progenitors that we have identified here may be the source of osteoblasts during the rapid phase of bone growth before LepR-cre-marked cells provide precursors for the osteoblast lineage. The demonstration of Col2-cre; R26R-tdTomato mice marking a large fraction of postnatal osteoblasts and stromal cells, including PαS cells, suggests that the adult mesenchymal precursor cells might derive from the progenitors that we have identified. Transition of these growth-associated progenitors into adult BMSCs seems to be infrequent and requires continuous inputs to make an easily discernible contribution. Further experiments will be required to establish the relationship between the growth-related mesenchymal progenitors identified here and adult mesenchymal precursors. The existence of these two populations provides opportunities for distinct regulation of the explosive growth of bone in early life and the much slower remodelling that occurs in adulthood.
METHODS
Methods and any associated references are available in the online version of the paper. Rosa26-loxP-stop-loxP-tdTomato (R26R-tdTomato, JAX7914) mice were acquired from Jackson laboratory. All procedures were conducted in compliance with the Guideline for the Care and Use of Laboratory Animals approved by Massachusetts General Hospital's Institutional Animal Care and Use Committee (IACUC). All mice were housed in a specific pathogen-free condition, and analysed in a mixed background. Mice were identified by micro-tattooing or ear tags. Tail biopsies of mice were lysed by a HotShot protocol (incubating the tail sample at 95 • C for 30 min in an alkaline lysis reagent followed by neutralization) and used for PCR-based genotyping (GoTaq Green Master Mix, Promega, and C1000 Touch Cycler, Bio-rad). Perinatal mice were also genotyped fluorescently (BLS miner's lamp) whenever possible. Mice were euthanized by over-dosage of carbon dioxide or decapitation under inhalation anaesthesia in a drop jar (Aerrane isoflurane, Henry Schein).
For the experiments in Fig. 1a -f, male mice (Col1-GFP; Col2-cre; R26R tdTomato/tdTomato or Osx-cre::GFP; R26R tdTomato/tdTomato mice) were mated to female CD1 mice (>8 weeks old, Charles River Laboratories) and the vaginal plug was checked in the morning. For the cell proliferation assay, 1 mg of 5-ethynyl-2 -deoxyuridine (EdU; Invitrogen A10044) dissolved in PBS was administered to pregnant mice three hours before euthanization at the indicated embryonic days. Embryos were used for analysis regardless of the sex. At least three embryos of the indicated genotype were examined at each time point shown in the figure.
For the experiments in Fig. 1g , male mice (Col1-GFP; Col2-cre; R26R tdTomato/tdTomato ; Runx2 +/− ) were mated to female Runx2 +/− mice. Embryos were used for analysis regardless of the sex. At least three embryos of the indicated genotype were examined at the time point shown in the figure.
For the experiments in Fig. 1h -m, male mice (Col1-GFP; Col2-cre; R26R tdTomato/tdTomato or Oc-GFP; Col2-cre; R26R tdTomato/tdTomato or Cxcl12-GFP; Col2cre; R26R tdTomato/tdTomato or Col1-GFP; Osx-cre::GFP; R26R tdTomato/tdTomato or Oc-GFP; Osx-cre::GFP; R26R tdTomato/tdTomato or Cxcl12GFP; Osx-cre::GFP; R26R tdTomato/tdTomato ) were mated to female CD1 mice. Pups at postnatal day 3 were used for analysis regardless of the sex. Three pups of the indicated genotype were examined at the time point shown in the figure. n = 3 mice per group.
For the experiments in Fig. 2 , male mice (Col1-GFP; Col2-creER; R26R tdTomato/tdTomato or Col2-creER; R26R tdTomato/tdTomato or Osx-creER; R26R tdTomato/tdTomato ) were mated to female CD1 mice and the vaginal plug was checked in the morning. Pregnant mice received 1 mg tamoxifen (Sigma T5648) and progesterone (Sigma P3972) intraperitoneally at an indicated embryonic day. Embryos or pups were used for analysis regardless of the sex. At least three embryos or pups of the indicated genotype were examined at the time point shown in the figure.
For the experiments in Figs 3 and 4, male mice (Col2-creER; R26R tdTomato/tdTomato or Col1-GFP; Col2-creER; R26R tdTomato/tdTomato or Cxcl12-GFP; Col2-creER; R26R tdTomato/tdTomato or Osx-creER; R26R tdTomato/tdTomato or Col1-GFP; Osx-creER; R26R tdTomato/tdTomato or Cxcl12-GFP; Osx-creER; R26R tdTomato/tdTomato ) were mated to female FVB/N mice (Charles River Laboratories) to generate pups. Three-day-old mice received 0.1 mg of tamoxifen intraperitoneally using a method reported previously 31 . Mice were used for analysis regardless of the sex. At least three mice of the indicated genotype were examined at the time point shown in the figure. For no-tamoxifen controls, the same amount of sunflower oil (without tamoxifen) was injected into three-day-old mice. For the experiments shown in Fig. 4i ,j, the number of mice used to plot the data was as follows: Col1-GFP; Col2-creER; R26R Tomato ; n = 4 (2 day chase), n = 3 (1 week chase), n = 5 (2 week chase), n = 3 (3 week chase) and n = 6 (4 week chase) mice; Cxcl12-GFP; Col2-creER; R26R Tomato ; n = 3 (2 day chase), n = 4 (1 week chase), n = 4 (2 week chase), n = 4 (3 week chase) and n = 4 (4 week chase) mice; Col1-GFP; Osx-creER; R26R Tomato ; n = 4 (2 day chase), n = 7 (1 week chase) and n = 3 (4 week chase) mice; Cxcl12-GFP; Osx-creER; R26R Tomato ; n = 3 (2 day chase), n = 3 (2 week chase) and n = 4 (4 week chase) mice.
For the experiments in Fig. 5a ,b, male mice (Col2-cre; R26R tdTomato/tdTomato or Osxcre::GFP; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate pups. Mice were used for analysis regardless of the sex. Four mice of the indicated genotype were examined.
For the experiments in Fig. 5c , male mice (Col2-creER; R26R tdTomato/tdTomato or Osx-creER; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate pups. Three-day-old mice received 0.1 mg of tamoxifen intraperitoneally. Mice were used for analysis regardless of the sex. Four mice of the indicated genotype were examined.
For the experiments in Fig. 5d ,e,h,i male mice (Cxcl12-GFP; Col2-cre; R26R tdTomato/tdTomato or Cxcl12-GFP; Osx-cre::GFP; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate mice. Mice were used for analysis regardless of the sex. Four mice of the indicated genotype were examined.
For the experiments in Fig. 5f ,g,j,k, male mice (Nes-GFP; Nes-creER; R26R tdTomato/tdTomato or Cxcl12-GFP; Col2-creER; R26R tdTomato/tdTomato or Cxcl12-GFP; Osx-creER; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate pups. Three-day-old mice received 0.1 mg of tamoxifen intraperitoneally. Mice were used for analysis regardless of the sex. For the experiments shown in Fig. 5g ,k, the number of mice used to plot the data was as follows: Nes-creER; R26R Tomato ; n = 5 (2 day chase), n = 3 (2 week chase) and n = 4 (4 week chase) mice; Col2-creER; R26R Tomato ; n = 4 (2 day chase), n = 5 (1 week chase), n = 7 (2 week chase), n = 5 (3 week chase) and n = 9 (4 week chase) mice; Osx-creER; R26R Tomato ; n = 6 (2 day chase), n = 5 (2 week chase) and n = 8 (4 week chase) mice.
For the experiments in Fig. 6 , male mice (Sox9-creER; R26R tdTomato/tdTomato or Col1-GFP; Sox9-creER; R26R tdTomato/tdTomato or Acan-creER; R26R tdTomato/tdTomato or Col1-GFP; Acan-creER; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate pups. Three-day-old mice received 0.1 mg of tamoxifen intraperitoneally. Mice were used for analysis regardless of the sex. At least three mice of the indicated genotype were examined at the time point shown in the figure. For no-tamoxifen controls, the same amount of sunflower oil (without tamoxifen) was injected into three-day-old mice. For experiments shown in Fig. 6j , the number of mice used to plot the data was as follows: Sox9-creER; R26R Tomato ; n = 3 (2 day chase) and n = 8 (4 week chase) mice; Col2-creER; R26R Tomato ; n = 4 (2 day chase) and n = 5 (4 week chase) mice; Acan-creER; R26R Tomato ; n = 3 (2 day chase) and n = 5 (4 week chase) mice.
For the experiments in Supplementary Fig. 4a , male mice (Nes-GFP; Col2-cre; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate pups. Mice were used for analysis regardless of the sex. Five mice of the indicated genotype were examined.
For the experiments in Supplementary Fig. 4b , male mice (Cxcl12-GFP; Col2-creER; R26R tdTomato/tdTomato ) were mated to female CD1 mice and the vaginal plug was checked in the morning. Pregnant mice received 1 mg tamoxifen and progesterone intraperitoneally at E13.5. Pups were used for analysis regardless of the sex. One pup of the indicated genotype was examined at P7.
For the experiments in Supplementary Fig. 4c , male mice (Cxcl12-GFP; Nes-creER; R26R tdTomato/tdTomato ) were mated to female FVB/N mice to generate pups. Three-day-old mice received 0.1 mg of tamoxifen intraperitoneally. Mice were used for analysis regardless of the sex. At least three mice of the indicated genotype were examined at the time point shown in the figure.
Tamoxifen. Tamoxifen (Sigma T5648) was mixed with 100% ethanol until completely dissolved. Subsequently, a proper volume of sunflower seed oil (Sigma S5007) was added to the tamoxifen-ethanol mixture and rigorously mixed. The tamoxifen-ethanol-oil mixture was incubated at 60 • C in a chemical hood until the ethanol evaporated completely. The tamoxifen-oil mixture was stored at room temperature until use.
Histology. Samples were dissected under a stereomicroscope (Nikon SMZ-10A) to remove soft tissues, and fixed in 4% paraformaldehyde, overnight at 4 • C, then decalcified in 15% EDTA for a proper period, typically ranging from 1 to 14 days. Decalcified samples were cryoprotected in 30% sucrose/PBS solutions and then in 30% sucrose/PBS:OCT (1:1) solutions, each overnight at 4 • C. Samples were embedded in an OCT compound (TissuTek, Sakura) under a stereomicroscope and transferred on a sheet of dry ice to solidify the compound. Embedded samples were cryosectioned at 15 µm using a cryostat (Leica CM1850). Images were captured with a wide-field fluorescence microscope (Nikon Eclipse E800) with prefigured triple-band filter settings for DAPI/FITC/TRITC, and merged with Spot Advanced Software (Spot Imaging) or an automated fluorescent microscope with a whole-slide scanning platform (TissueFAXS, TissueGnostics). Confocal images were acquired using LSM510 and Zen2009 software (Zeiss) with lasers and corresponding bandpass filters for DAPI (Ex. 405 nm, BP420-480), GFP (Ex. 488 nm, BP505-530), tdTomato (Ex. 543 nm, BP565-595) and Alexa633 (Ex. 633 nm, LP650). LSM Image Viewer and Adobe Photoshop software were used to capture and align images. Representative images of at least three independent biological samples are shown in the figures.
Flow cytometry. Femurs, tibias, iliac crests and humeri were carefully dissected and gently crushed in 5 ml Ca 2+ , Mg 2+ -free HBSS (Sigma) with a pestle and a mortar (Coors Tek), and then supernatants were filtered through a 70 µm cell strainer (Fisher) into a 50 ml tube on ice. Bone fragments were crushed for two additional times in 5 ml HBSS and supernatants were filtered into the same tube. Tissue remnants were incubated with 2 Wünsch units of Liberase TM (Roche) at 37 • C for 45 min on a shaking incubator (Thermomixer, Eppendorf). For experiments to collect osteoblasts, 0.25% trypsin-EDTA (Gibco) was added. Cells were mechanically triturated using an 18-gauge needle and a 1 ml syringe (BD) and filtered into the same tube. Cells were pelleted, resuspended and layered over Ficoll-Paque PLUS (GE Healthcare) to collect low-density cell fractions. Cells were stained with anti-mouse CD45-APC, CD45-eFluor 450, Ter119-eFluor 450, Sca1-Alexa Fluor 700 (1:500, eBioscicence), PDGFRα (CD140a)-APC (1:250, eBioscience) or their isotype controls (1:500, eBioscience) in DPBS/2%FBS on ice for 30 min. Flow cytometry was performed using a four-laser BD LSRII (Ex.355/407/488/633nm) and FACSDiva, and analysed on FlowJo (TreeStar). Representative plots of at least three independent biological samples are shown in the figures.
Immunohistochemisty. Cryosections were stored at −20 • C in freezers until use.
Sections were postfixed in 4% paraformaldehyde for 15 min, blocked with 2% BSA/TBST for 30 min and incubated with rat anti-CD31 monoclonal antibody (1:100, AbD Serotec MCA2388), overnight at 4 • C, and subsequently with Alexa Fluor 633-conjugated goat anti-rat IgG (1:400, Invitrogen A21087) for 3 h at 4 • C. For lipid staining, cryosections were gently rinsed with TBS and incubated with LipidTOX Deep Red (1:200, Invitrogen H34477) for 30 min at room temperature. Sections were further incubated with DAPI (4 ,6-diamidino-2phenylindole, Invitrogen D1306) to stain nuclei. Stained samples were coverslipped and mounted in a mounting medium for fluorescence imaging (Vectashield H-1000, Vector Labs). The edge of the coverslip was coated with commercially available transparent nail polish.
Cell proliferation assay. To evaluate cell proliferation, 1 mg of 5-ethynyl-2'deoxyuridine (EdU; Invitrogen A10044) dissolved in PBS was administered to pregnant mice three hours before euthanization at the indicated embryonic days. Click-iT Imaging Kit (Invitrogen, C10337) with Alexa Fluor 647-azide (Invitrogen A10277) was used to detect EdU in cryosections.
Colony-forming unit fibroblast (CFU-F) assay. Bone marrow cells were collected as described in the Flow cytometry section. Bone marrow nucleated cells (10 6 ) were plated into a 9.6 cm 2 glass-bottom chamber slide (Lab-Tek II, Nunc) and cultured in MesenCult Proliferation medium for mouse cells (StemCell Technologies) for 10 days. Cells were fixed in 4% paraformaldehyde, for 30 min at 4 • C and counterstained with wheat germ agglutinin-Alexa Fluor 488 conjugate (Invitrogen W11261) for 15 min. Representative images from at least three independent biological samples are shown in the figures.
Statistical Analysis.
Results are presented as mean values ± s.d. Statistical evaluation was conducted using the Mann-Whitney's U -test. A P value of <0.05 was considered significant. No statistical method was used to predetermine sample size. Sample size was determined on the basis of previous literature and our previous experience to give sufficient standard deviations of the mean so as not to miss a biologically important difference between groups. The experiments were not randomized. All of the available mice of the desired genotypes were used for experiments. The investigators were not blinded during experiments and outcome assessment. One femur from each mouse was arbitrarily chosen for histological analysis. Genotypes were not particularly highlighted during quantification.
